Abeona Management to Present at Multiple Conferences in November
(Thomson Reuters ONE) -
NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics
Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused
on developing novel cell and gene therapies for life-threatening rare genetic
diseases, today announced the Company's senior management team will participate
in the following conferences:
Jefferies 2017 London Healthcare Conference
Date: Wednesday, November 15th
Presentation time: 4:00 PM GMT
Location: London, England
Webcast: http://wsw.com/webcast/jeff108/abeo/index.aspx
8th World Orphan Drug Congress
Date: Tuesday, November 14th
Location: Barcelona, Spain
Website: http://www.terrapinn.com/conference/world-orphan-drug-
congress/index.stm
Barclays Gene Editing & Gene Therapy Day
Date: Thursday, November 30th
Presentation time: 10:40 AM EST
Location: New York, NY
About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for life-threatening rare genetic
diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated
virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-
101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa
(RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome
type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease
(JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-
201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA)
disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to
gene therapy for rare blood diseases. In addition, Abeona is developing a
proprietary vector platform, AIM(TM), for next generation product candidates.
For more information, visit www.abeonatherapeutics.com.
Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212)786-6212
csilverstein(at)abeonatherapeutics.com
Media Contact:
Lynn Granito
Berry & Company Public Relations
+1 (212) 253-8881
lgranito(at)berrypr.com
This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements are subject to numerous risks
and uncertainties, including but not limited to continued interest in our rare
disease portfolio, our ability to enroll patients in clinical trials, the impact
of competition; the ability to develop our products and technologies; the
ability to obtain any necessary intellectual property to commercialize any of
our products; the ability to achieve or obtain necessary regulatory approvals
and licenses; the impact of changes in the financial markets and global economic
conditions; and other risks as may be detailed from time to time in the
Company's Annual Reports on Form 10-K and other reports filed by the Company
with the Securities and Exchange Commission. The Company undertakes no
obligations to make any revisions to the forward-looking statements contained in
this release or to update them to reflect events or circumstances occurring
after the date of this release, whether as a result of new information, future
developments or otherwise.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.11.2017 - 14:45 Uhr
Sprache: Deutsch
News-ID 567850
Anzahl Zeichen: 4190
contact information:
Town:
Dallas
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 224 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Abeona Management to Present at Multiple Conferences in November"
steht unter der journalistisch-redaktionellen Verantwortung von
Abeona Therapeutics Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
